The U.S. in vitro fertilization market size is anticipated to reach USD 7.24 billion by 2030, expanding at a CAGR of 4.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of infertility among couples, the continuous advancements in IVF technology and techniques, and the shift in societal norms and attitudes toward family have significantly contributed to the increasing demand for IVF services in the U.S.
The regulatory landscape surrounding assisted reproductive technologies, including IVF, also influences market dynamics. Regulations governing IVF practices, clinic accreditation standards, and ethical considerations impact the accessibility and quality of IVF services in the U.S. Changes in regulations can either facilitate or hinder market growth by affecting factors such as treatment costs, clinic operations, and patient safety.
Increased public awareness about infertility issues and available treatment options has played a crucial role in driving the growth of the U.S. IVF market. Educational campaigns, media coverage, and advocacy efforts have helped destigmatize infertility and promote understanding about fertility treatments like IVF. Greater awareness empowers individuals to make informed decisions about seeking fertility assistance through IVF.
Request a free sample copy or view report summary: U.S. In Vitro Fertilization Market Report
Based on instruments, the culture media segment dominated the market with around 40% share in 2023 owing to as availability of funding and an increase in research activities
The disposable devices segment is expected to grow at the fastest CAGR over the forecast period
Based on procedure type, the fresh non-donor segment held the largest market share of over 45% in 2023. Fresh cycles are often perceived as more cost-effective due to potentially requiring fewer treatment cycles to achieve a successful pregnancy
Frozen donors are expected to register the fastest CAGR during the forecast period owing to the convenience and flexibility offered by them
The fertility clinics segment dominated the market with around 80% share in 2023 and is expected to grow at the fastest CAGR over the forecast period
The increasing demand for ART treatments has led to a significant rise in the number of fertility clinics and ART centers
In October 2023, Merck & Co. announced the launch of Fertility benefit program with the aim to provide financial services to employees for fertility treatments. The range of services includes IVF treatments, fertility tests, and hormonal treatments
Grand View Research has segmented the U.S. in vitro fertilization market based on instruments, procedure type, and end-use:
U.S. In Vitro Fertilization Instrument Outlook (Revenue, USD Billion, 2018 - 2030)
Disposable Devices
Culture Media
Cryopreservation Media
Embryo Culture Media
Ovum Processing Media
Sperm Processing Media
Capital Equipment
Sperm Analyzer Systems
Imaging Systems
Ovum Aspiration Pumps
Micromanipulator Systems
Incubators
Gas Analyzers
Laser Systems
Cryosystems
Sperm Separation Devices
IVF Cabinets
Anti-vibration Tables
Witness Systems
Other
U.S. In Vitro Fertilization Procedure Type Outlook (Revenue, USD Billion, 2018 - 2030)
Fresh Donor
Frozen Donor
Fresh Non-Donor
Frozen Non-Donor
U.S. In Vitro Fertilization End-use Outlook (Revenue, USD Billion, 2018 - 2030)
Fertility Clinics
Hospitals & Others Setting
List of Key Players in the U.S. in Vtro Fertilization market
Bayer AG
Cook Medical LLC
EMD Serono, Inc.
Ferring B.V.
FUJIFILM Irvine Scientific (FUJIFILM Holdings Corporation)
Genea Biomedx
EMD Serono, Inc. (Merck KGaA)
Merck & Co., Inc.
The Cooper Companies, Inc.
Thermo Fisher Scientific, Inc.
Vitrolife
Nova IVF
RMA Network (Reproductive Medicine Associates)
U.S. Fertility
"The quality of research they have done for us has been excellent..."